1-8 of 8
Sean Buchanan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B108: Antitumor efficacy of EGFR antibody necitumumab and dual PI3K/mTOR inhibitor (LY3023414) in preclinical tumor models

Maxine A. Melchior, Xuemei Guo, Gregory P. Donoho, Philip W. Iversen, Thompson N. Doman, Manisha Brahmachary, Xueqian Gong, Gerald E. Hall, Jason R. Manro, Yung-mae M. Yao, Sean Buchanan, Tod Smeal, Michael D. Kalos, Ruslan D. Novosiadly
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B108.
https://doi.org/10.1158/1535-7163.TARG-17-B108
Published: 01 January 2018
View article titled, Abstract B108: Antitumor efficacy of EGFR antibody necitumumab and dual PI3K/mTOR inhibitor (LY3023414) in preclinical tumor models
Journal Articles

Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration

Genshi Zhao, Colin F. Green, Yu-Hua Hui, Lourdes Prieto, Robert Shepard, Sucai Dong, Tao Wang, Bo Tan, Xueqian Gong, Lisa Kays, Robert L. Johnson, Wenjuan Wu, Shobha Bhattachar, Miriam Del Prado, James R. Gillig, Maria-Carmen Fernandez, Ken D. Roth, Sean Buchanan, Ming-Shang Kuo, Sandaruwan Geeganage, Timothy P. Burkholder
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (12): 2677–2688.
https://doi.org/10.1158/1535-7163.MCT-16-0674
Published: 03 December 2017
View article titled, Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration
Open the PDF for Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration in another window
Includes: Supplementary data
Journal Articles

Abstract A24: Beta-klotho expression is associated with the antitumor activity of pan-FGFR inhibitor in human malignancies with FGF19 amplification

Amelie Forest, Sandra Nakasone, Ying Wang, Xuemei Guo, Timothy R. Mack, Genshi Zhao, Yong G. Yue, Xueqian Gong, Trent Stewart, Sean Buchanan, Christoph Reinhard, Ruslan Novosiadly
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A24.
https://doi.org/10.1158/1535-7163.TARG-15-A24
Published: 01 December 2015
View article titled, Abstract A24: Beta-klotho expression is associated with the antitumor activity of pan-FGFR inhibitor in human malignancies with FGF19 amplification
Journal Articles

Abstract C88: The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.

Vipin Yadav, Teresa F. Burke, Lysiane Huber, Robert D. Van Hoen, Youyan Zhang, Sean Buchanan, Edward M. Chan, James J. Starling, Richard P. Beckmann, Sheng-Bin Peng
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C88.
https://doi.org/10.1158/1535-7163.TARG-13-C88
Published: 01 November 2013
View article titled, Abstract C88: The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.
Journal Articles

Abstract B229: TBKI kinase inhibition blocks RANTES secretion and exhibits minimal tumor growth inhibition in oncogenic Ras-driven tumor models.

Robert Van Horn, Tinggui Yin, Xiaoyi Zhang, Chunping Yu, Youyan Zhang, Xue-Qian Gong, Sean Buchanan, Xiang S. Ye, William McMillen, David Barda, Sheng-Bin Peng
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B229.
https://doi.org/10.1158/1535-7163.TARG-13-B229
Published: 01 November 2013
View article titled, Abstract B229: TBKI kinase inhibition blocks RANTES secretion and exhibits minimal tumor growth inhibition in oncogenic Ras-driven tumor models.
Journal Articles

SGX70393 inhibits the T315I mutant of Bcr-Abl kinase and pre-empts drug resistance when combined with nilotinib or dasatinib

Thomas O'Hare, Christopher Eide, Jeffrey Tyner, Amie Corbin, Matthew Wong, Sean Buchanan, Kevin Holme, Katayoun Jessen, Crystal Tang, Hal Lewis, Richard Romero, Stephen Burley, Michael Deininger
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A259.
Published: 01 November 2007
View article titled, SGX70393 inhibits the T315I mutant of Bcr-Abl kinase and pre-empts drug resistance when combined with nilotinib or dasatinib
Journal Articles

Selective inhibition of MET protein receptor tyrosine kinase by SGX523

Steven Gessert, Brandon Aubol, Tuan Do, Jorg Hendle, Patrick Lee, Katayoun Jessen, Karen Froning, Jeremy Felce, J. Michael Sauder, Kenneth Schwinn, Jeff Blaney, Stephen Burley, Siegfried Reich, Sean Buchanan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C198.
Published: 01 November 2007
View article titled, Selective inhibition of MET protein receptor tyrosine kinase by SGX523
Journal Articles

In vitro and in vivo antitumor activities of SGX523, a novel MET inhibitor

Katayoun Jessen, Karen Froning, Jeremy Felce, Andres Gutierrez, Marshall Peterman, Stephanie Leonard, Crystal Tang, Nanni Huser, Sam Sperry, Natalie Tran, Yousif Sahly, Steven Gessert, Stephen Burley, Siegfried Reich, Sean Buchanan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B233.
Published: 01 November 2007
View article titled, <em>In vitro</em> and <em>in vivo</em> antitumor activities of SGX523, a novel MET inhibitor